Morning Overview on MSN
Magic mushroom therapy just jumped closer to FDA approval
The U.S. Food and Drug Administration issued its first formal guidance on how to design and run clinical trials for ...
Filing acceptance based on phase III data showing giredestrant plus everolimus reduced the risk of disease progression or ...
Filing acceptance based on Phase III data showing giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1-mutated populations, respectively, versus ...
It would be understandable if you stopped thinking as much about Pluto after it was “demoted” from being considered one of the nine planets sharing the Earth’s solar system to being classified as a ...
Travere Therapeutics (NASDAQ:TVTX) highlighted record demand for FILSPARI in IgA nephropathy (IgAN), provided an update on the U.S. Food and Drug Administration’s review timeline for a potential focal ...
Imagine a material cracking—now imagine what happens if there are small inclusions in the material. Do they create an ...
U.S. consumers pay higher prices for drugs to help pay for research and development, about 2.78 times higher than in Organisation for Economic Co-operation and Development (OECD) countries like Canada ...
Moderna Inc. MRNA shares are up on Wednesday as the company has received positive news regarding its investigational flu vaccine, mRNA-1010. The stock’s movement comes after the U.S. Food and Drug ...
The FDA is slated to make a decision on the flu shot on Aug. 5, which will allow Moderna to make the vaccine available for ...
The FDA has accepted Moderna’s revised influenza vaccine filing days after controversially refusing to review the original submission, putting the biotech on track to win approval in time for the 2026 ...
Recent US drug pricing reforms adopt international prices shaped by quality-adjusted life-year (QALY)-based assessments, despite longstanding federal prohibitions on using QALYs in coverage and ...
NEXSPIKE is the third Moderna vaccine authorized in the European Union, strengthening the Company's respiratory vaccine portfolio in Europe ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results